Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
HAUPPAUGE, N.Y., Aug. 09, 2017 -- United-Guardian, Inc. (NASDAQ:UG) reported today that sales for the second quarter of 2017 increased by 76% compared with the same period last year, growing from $2,215,952 to $3,891,656. As a result, net income for the quarter increased 172% from $405,381 ($0.09 per share) to $1,104,149 ($0.24 per share). For the six-month period ended June 30, 2017, sales increased by 49% and net income increased by 87%, resulting in earnings per share of $0.38 compared with $0.20 for the comparable 6-month period in 2016.
Ken Globus, President of United-Guardian, stated, "As a result of the resumption of shipments of one of our personal care products to China, as well as an increase in sales of our new single-dose form of Renacidin® Irrigation, our most important pharmaceutical product, we were able to significantly increase our sales and earnings for the second quarter of this year compared with the same period last year. Overall, sales of our personal care products increased by 131% compared with last year’s second quarter, and by 82% when compared with the first six months of 2016. In addition, pharmaceutical sales increased by 40% for the second quarter of 2017 compared with last year’s second quarter, and by 46% for the first six months of 2017 compared with the same period last year. We remain optimistic that we will continue to see strong sales of both of these product lines as the year progresses.”
United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.
NOTE: This press release contains both historical and "forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company’s expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the “safe harbor” provisions of that Act. Such statements are subject to a variety of factors that could cause our actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company’s business please refer to the company's reports and filings with the Securities and Exchange Commission.
| RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017 and 2016 | |||||||||||||
| THREE MONTHS ENDED JUNE 30, | SIX MONTHS ENDED JUNE 30, | ||||||||||||
| 2017 | 2016 | 2017 | 2016 | ||||||||||
| Sales: | |||||||||||||
| Gross sales | $ | 3,891,656 | $ | 2,215,952 | $ | 6,764,379 | $ | 4,546,529 | |||||
| Sales rebates and allowances | (116,905 | ) | (76,787 | ) | (203,240 | ) | (144,788 | ) | |||||
| Net Sales | 3,774,751 | 2,139,165 | 6,561,139 | 4,401,741 | |||||||||
| Costs and expenses: | |||||||||||||
| Cost of sales | 1,667,113 | 1,007,666 | 2,931,209 | 1,905,391 | |||||||||
| Operating expenses | 418,605 | 465,329 | 882,085 | 932,885 | |||||||||
| Research and development | 158,275 | 157,895 | 348,004 | 335,461 | |||||||||
| Total costs and expenses | 2,243,993 | 1,630,890 | 4,161,298 | 3,173,737 | |||||||||
| Income from operations | 1,530,758 | 508,275 | 2,399,841 | 1,228,004 | |||||||||
| Investment income | 72,796 | 82,906 | 125,668 | 126,218 | |||||||||
| Income before provision for income taxes | 1,603,554 | 591,181 | 2,525,509 | 1,354,222 | |||||||||
| Provision for income taxes | 499,405 | 185,800 | 786,925 | 423,750 | |||||||||
| Net Income | $ | 1,104,149 | $ | 405,381 | $ | 1,738,584 | $ | 930,472 | |||||
| Earnings per common share (Basic and Diluted) | $ | 0.24 | $ | .09 | $ | 0.38 | $ | 0.20 | |||||
Additional financial information can be found at the company’s web site at www.u-g.com.
Contact: Robert S. Rubinger Public Relations (631) 273-0900
